BOSENTAN VS PLACEBO IN NYHA CLASS I/II SCLERODERMA PATIENTS WITH EXERCISE INDUCE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 硬皮病患者发生肺动脉高压(PAH)的风险很高。我们知道，在PAH中发现的一些异常发生在明确诊断PAH之前多年。运动性PAH发生在特发性PAH中，我们发现47%的无明确PAH的硬皮病患者的肺压力升高。这项研究是波生坦的双盲对照试验，波生坦是已获批准的治疗PAH的方法之一，与安慰剂相比，研究进行了4个月。这将决定早期PAH的任何更微妙的发现是否对波生坦有反应。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Scleroderma patients have a high risk for developing pulmonary hypertension (PAH). We know that some of the abnormalities found in PAH occur many years prior to the definite diagnosis of PAH. Exercise induced PAH occurs in idiopathic PAH, and we have found that 47% of scleroderma patients without definite PAH have increases in the pulmonary pressures. This study is a double blind controlled trial of bosentan, one of the approved treatments for PAH, vs placebo in a 4 month study. It will determine whether any of the more subtle findings of early PAH respond to bosentan.